Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,333 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $55.69, for a total value of $4,640,814.77. Following the sale, the chief executive officer now owns 272,768 shares of the company’s stock, valued at $15,190,449.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Nektar Therapeutics (NASDAQ NKTR) opened at $56.90 on Monday. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $57.83.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. The business had revenue of $152.90 million during the quarter, compared to analyst estimates of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The business’s revenue was up 321.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.32) earnings per share. sell-side analysts anticipate that Nektar Therapeutics will post -0.75 EPS for the current fiscal year.

Several equities research analysts have commented on NKTR shares. Roth Capital set a $45.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Canaccord Genuity Group boosted their price objective on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Mizuho boosted their price objective on Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Cowen started coverage on Nektar Therapeutics in a research note on Tuesday, November 7th. They set an “outperform” rating for the company. Finally, ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $35.58.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its position in shares of Nektar Therapeutics by 0.9% in the second quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock valued at $395,330,000 after purchasing an additional 185,933 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Nektar Therapeutics by 3.0% in the second quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock valued at $273,893,000 after purchasing an additional 401,914 shares in the last quarter. State Street Corp grew its position in shares of Nektar Therapeutics by 11.3% in the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after purchasing an additional 447,023 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Nektar Therapeutics by 87.8% in the third quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock valued at $79,903,000 after purchasing an additional 1,556,352 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Nektar Therapeutics by 0.6% in the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock valued at $41,812,000 after purchasing an additional 12,730 shares in the last quarter. Institutional investors and hedge funds own 96.04% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/nektar-therapeutics-nktr-ceo-sells-4640814-77-in-stock/1770664.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.